

This is a promotional meeting organized and fully funded by Sandoz for UK HCPs only.



AFQLIR®
Aflibercept

Unlocking the Potential of Biosimilars in Ophthalmology with Afqlir®



For prescribing
information
please scan the
QR code



Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK). Adverse events should also be reported to Sandoz via adverse.event.uk@sandoz.com or online through the pharmacovigilance intake (PVI) tool at <https://pvi1j.solutions.iqvia.com>



AFQLIR[®]
Aflibercept

Sandoz is pleased to invite you to a **congress symposium** at the **RCO Annual Congress 2026**, where we will explore the **potential of biosimilars in ophthalmology** through clinical experience with **Afqlir[®]**, its **real-world outcomes**, and the **value it delivers to the NHSE**.

Symposium

Unlocking the Potential of Biosimilars in Ophthalmology with Afqlir[®]

Clinical Confidence, Real-World Outcomes, and the Value Delivered to NHSE



Serena Salvatore

Consultant Ophthalmologist
Clinical Lead, Medical Retina
& Clinical Research Unit -
Bristol Eye Hospital



Amit Nakum

SpaMedica, Medical
Retina Service Lead



Bhavana Reddy

Head of Pharmacy and Clinical Support
Pharmacy and Clinical Support Team |
Medicines Value and Access
NHS England (National)



20th May
2026



12:30 – 13:30



RCO Annual Congress 2026,
Manchester
Room No. **Exchange Room 11**

We look forward to seeing you there.

Sandoz product will be mentioned during the meeting. UK prescribing information and adverse event reporting details are available on the reverse of the leaflet.

SANDOZ